SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 47 filers reported holding SYNDAX PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $917,548 | -37.5% | 63,192 | -9.9% | 0.00% | -50.0% |
| Q2 2023 | $1,467,905 | +0.0% | 70,134 | +0.9% | 0.00% | 0.0% |
| Q1 2023 | $1,467,544 | -15.1% | 69,486 | +2.3% | 0.00% | -33.3% |
| Q4 2022 | $1,728,259 | +15.8% | 67,908 | +9.3% | 0.00% | 0.0% |
| Q3 2022 | $1,493,000 | +28.4% | 62,140 | +2.8% | 0.00% | +50.0% |
| Q2 2022 | $1,163,000 | +21.7% | 60,462 | +9.9% | 0.00% | +100.0% |
| Q1 2022 | $956,000 | -23.8% | 54,994 | -4.1% | 0.00% | 0.0% |
| Q4 2021 | $1,255,000 | +17.6% | 57,318 | +2.6% | 0.00% | 0.0% |
| Q3 2021 | $1,067,000 | +0.2% | 55,847 | -10.0% | 0.00% | 0.0% |
| Q2 2021 | $1,065,000 | +1.5% | 62,028 | +32.2% | 0.00% | 0.0% |
| Q1 2021 | $1,049,000 | +15.9% | 46,910 | +15.3% | 0.00% | 0.0% |
| Q4 2020 | $905,000 | +50.8% | 40,671 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $600,000 | -0.3% | 40,671 | +0.1% | 0.00% | 0.0% |
| Q2 2020 | $602,000 | +61.4% | 40,614 | +19.4% | 0.00% | 0.0% |
| Q1 2020 | $373,000 | +38.1% | 34,027 | +10.8% | 0.00% | – |
| Q4 2019 | $270,000 | +16.9% | 30,704 | -0.8% | 0.00% | – |
| Q3 2019 | $231,000 | -19.8% | 30,950 | 0.0% | 0.00% | -100.0% |
| Q2 2019 | $288,000 | +142.0% | 30,950 | +36.4% | 0.00% | – |
| Q1 2019 | $119,000 | +17.8% | 22,688 | 0.0% | 0.00% | – |
| Q4 2018 | $101,000 | -44.8% | 22,688 | 0.0% | 0.00% | – |
| Q3 2018 | $183,000 | +15.1% | 22,688 | 0.0% | 0.00% | – |
| Q2 2018 | $159,000 | -38.6% | 22,688 | +24.7% | 0.00% | -100.0% |
| Q1 2018 | $259,000 | +58.9% | 18,197 | -2.0% | 0.00% | – |
| Q4 2017 | $163,000 | -19.7% | 18,561 | +6.8% | 0.00% | – |
| Q3 2017 | $203,000 | -6.9% | 17,387 | +11.5% | 0.00% | – |
| Q2 2017 | $218,000 | +63.9% | 15,587 | +60.9% | 0.00% | – |
| Q1 2017 | $133,000 | +90.0% | 9,687 | -1.0% | 0.00% | – |
| Q4 2016 | $70,000 | -52.7% | 9,787 | 0.0% | 0.00% | – |
| Q3 2016 | $148,000 | +52.6% | 9,787 | -1.0% | 0.00% | – |
| Q2 2016 | $97,000 | – | 9,887 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |